[
  {
    "ts": null,
    "headline": "Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors",
    "summary": "NEW BRUNSWICK, N.J., September 08, 2025--Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors.",
    "url": "https://finnhub.io/api/news?id=984511fb9f9a375ba41747df47966537055d6333a8b4f1e7d7f30dee545fb9cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757373420,
      "headline": "Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors",
      "id": 136674232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW BRUNSWICK, N.J., September 08, 2025--Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors.",
      "url": "https://finnhub.io/api/news?id=984511fb9f9a375ba41747df47966537055d6333a8b4f1e7d7f30dee545fb9cc"
    }
  },
  {
    "ts": null,
    "headline": "A new class of sleep drugs draws Wall Street’s attention",
    "summary": "Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.",
    "url": "https://finnhub.io/api/news?id=fbe305baad7567dd47a572b696c67955e3951a0e83bef61f185d1f83ee41fcfb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757350080,
      "headline": "A new class of sleep drugs draws Wall Street’s attention",
      "id": 136674233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.",
      "url": "https://finnhub.io/api/news?id=fbe305baad7567dd47a572b696c67955e3951a0e83bef61f185d1f83ee41fcfb"
    }
  },
  {
    "ts": null,
    "headline": "J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?",
    "summary": "ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.",
    "url": "https://finnhub.io/api/news?id=3ce7ff8fd165f8dfca9e5195db735cd7ffcd2b1bd13bb4fb0bd0d0b7eeebcf04",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757340900,
      "headline": "J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?",
      "id": 136674234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.",
      "url": "https://finnhub.io/api/news?id=3ce7ff8fd165f8dfca9e5195db735cd7ffcd2b1bd13bb4fb0bd0d0b7eeebcf04"
    }
  },
  {
    "ts": null,
    "headline": "Take the Zacks Approach to Beat the Markets: Hecla Mining, GE Aerospace & Stride in Focus",
    "summary": "Zacks highlights Hecla Mining, GE Aerospace, and Stride as standout performers in a volatile market, driven by earnings trends and stock upgrades.",
    "url": "https://finnhub.io/api/news?id=937bb7545eb59657e7036a9e6b923f8729805899cf07cb992e4559d7b4e66495",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757335260,
      "headline": "Take the Zacks Approach to Beat the Markets: Hecla Mining, GE Aerospace & Stride in Focus",
      "id": 136669107,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Zacks highlights Hecla Mining, GE Aerospace, and Stride as standout performers in a volatile market, driven by earnings trends and stock upgrades.",
      "url": "https://finnhub.io/api/news?id=937bb7545eb59657e7036a9e6b923f8729805899cf07cb992e4559d7b4e66495"
    }
  },
  {
    "ts": null,
    "headline": "Ronovo Surgical raises $67M, led by J&J venture arm",
    "summary": "Ronovo, a Chinese surgical robotics company, will also team with a J&J subsidiary in Shanghai to sell Ronovo’s soft tissue platform and complementary J&J technologies.",
    "url": "https://finnhub.io/api/news?id=0847cece1d9a9241159736427f465ab5fae175bdce5ca26c14c39d42b47d4bda",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757329881,
      "headline": "Ronovo Surgical raises $67M, led by J&J venture arm",
      "id": 136674235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Ronovo, a Chinese surgical robotics company, will also team with a J&J subsidiary in Shanghai to sell Ronovo’s soft tissue platform and complementary J&J technologies.",
      "url": "https://finnhub.io/api/news?id=0847cece1d9a9241159736427f465ab5fae175bdce5ca26c14c39d42b47d4bda"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point",
    "summary": "Bristol-Myers Squibbâs strong oncology sales and upcoming approvals make its stockâs risk/reward profile increasingly attractive. Read more here on BMY stock here.",
    "url": "https://finnhub.io/api/news?id=e1c9b0b9fdecd0ec7458ae8850bbc3edb9bed3985e2a2c5b877217882f2dabc0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757324865,
      "headline": "Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point",
      "id": 136668842,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227488268/image_1227488268.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibbâs strong oncology sales and upcoming approvals make its stockâs risk/reward profile increasingly attractive. Read more here on BMY stock here.",
      "url": "https://finnhub.io/api/news?id=e1c9b0b9fdecd0ec7458ae8850bbc3edb9bed3985e2a2c5b877217882f2dabc0"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: All-Time Highs In Sight After Raised Guidance And A Technical Breakout",
    "summary": "I reiterate my buy rating on JNJ, supported by steady EPS growth, robust free cash flow, and an attractive valuation.",
    "url": "https://finnhub.io/api/news?id=152555ce38123dde7a070bc1e0d52afae33c94594d1e6c80925bdbc4a6c6beee",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757318462,
      "headline": "Johnson & Johnson: All-Time Highs In Sight After Raised Guidance And A Technical Breakout",
      "id": 136668405,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "I reiterate my buy rating on JNJ, supported by steady EPS growth, robust free cash flow, and an attractive valuation.",
      "url": "https://finnhub.io/api/news?id=152555ce38123dde7a070bc1e0d52afae33c94594d1e6c80925bdbc4a6c6beee"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs",
    "summary": "Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.",
    "url": "https://finnhub.io/api/news?id=7ff15342da5ffe044e2eb13a1d532421323b86ad8fcc88d283203eb5cf3587c4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757316643,
      "headline": "Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs",
      "id": 136668317,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196154167/image_2196154167.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why LLY stock is rated a 'Buy' now.",
      "url": "https://finnhub.io/api/news?id=7ff15342da5ffe044e2eb13a1d532421323b86ad8fcc88d283203eb5cf3587c4"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: A Safe Hold, But Lacking Catalysts To Beat The Market",
    "summary": "Johnson & Johnson's business is in a stable, mature phase, suggesting slow yet steady growth. Click here to read why JNJ stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=bde9a10f9959adaf761ea6442ddc3682fe3e55d314f450b33711727d0bd88d52",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757304326,
      "headline": "Johnson & Johnson: A Safe Hold, But Lacking Catalysts To Beat The Market",
      "id": 136667555,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Johnson & Johnson's business is in a stable, mature phase, suggesting slow yet steady growth. Click here to read why JNJ stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=bde9a10f9959adaf761ea6442ddc3682fe3e55d314f450b33711727d0bd88d52"
    }
  }
]